The benefits observed after the administration of SGLT2 inhibitors in diabetics and non-diabetics with and without HF and or CKD [2,3,4,5,6,7,8,9,10] are probably the culmination of the primary metabolic/renal and secondary myocardial benefits as described above. The gene discussed is SLC5A2; the disease is chronic kidney disease.